Umbilical cord blood stem cell transplantation for the treatment of diabetic foot in 23 cases

Lü-yun Zhu,Guang-yu Wang,Li-cheng Ma,Li-ye Hu,Xiao-ling Li,Shao-ling Yang,Wei Shan,Rong-rong Hou
DOI: https://doi.org/10.3969/j.issn.1673-8225.2012.01.038
2012-01-01
Abstract:Background: Transplantation of autologous bone-marrow mononuclear cells or umbilical cord derived mesenchymal stem cells for treatment of diabetic foot has been widely developed at present, which showed good curative effect on ischemic lesions and peripheral neuropathy. Objective: To observe the effect of umbilical cord derived mononuclear cells on diabetic ischemic lesions and peripheral neuropathy. Methods: Twenty-three patients with diabetic foot received umbilical cord derived mononuclear cells injection into both lower extremities intramuscular (1-3 mL/site) for 3 cm distance after dilution. The number of implanted cells was 1.23×108 -1.06×109 per leg (totally 38 limbs). Results and Conclusion: There was no significant difference in ankle/brachial index after treatment. There were significant differences in angina cruris, skin temperature and transcutaneous oxygen partial pressure after 3 or 6 months treatment. After treatment for 6 months, the pain score and thermoesthesia score were improved and there were significant differences in rational symptom score, clinical examination score, the value of pallesthetic sensibility and the conduction velocity of motor/sensory nerves. The clinical symptoms and objective indexes of diabetic ischemic lesions and peripheral neuropathy were improved after umbilical cord derived mononuclear cells implantation.
What problem does this paper attempt to address?